Madrigal's lead therapy is driving 127% year-over-year revenue growth — the highest rate in its industry cohort — and the risk/reward of approximately 2.6-to-1 remains favorable with 18% upside to the consensus target, but two consecutive earnings misses before the most recent quarter, a 20% short interest, and single-product dependency require evidence of sustained execution before the setup becomes fully compelling.
Thesis pillars
- Earnings Execution Inconsistency↑Improving
- Industry Leading Revenue Acceleration→Stable
- Single Product Regulatory Concentration↓Deteriorating
- +1 more pillar — see the Why tab for full reasoning
Pillars as of Jul 3, 2026, based on the 10-K filed Feb 19, 2026· older than 90 days
Madrigal Pharmaceuticals, Inc. (MDGL) Stock Analysis
Oversold Bounce setup
Healthcare · Biotechnology
Sell if holding. Engine safety override at $400.43: Risk below floor (2.1 < 2.5) triggers a hard block regardless of the otherwise-positive setup — overall score 6.6/10 and A.R:R 4.6:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 11%; Elevated put/call ratio: 6.40; Below-average business quality.
Madrigal Pharmaceuticals is a biopharmaceutical company whose sole commercialized product, Rezdiffra (resmetirom), received FDA accelerated approval in March 2024 as the first therapy for noncirrhotic MASH with moderate-to-advanced liver fibrosis. Rezdiffra generated $958.4... Read more
Sell if holding. Engine safety override at $400.43: Risk below floor (2.1 < 2.5) triggers a hard block regardless of the otherwise-positive setup — overall score 6.6/10 and A.R:R 4.6:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 11%; Elevated put/call ratio: 6.40; Below-average business quality. Chart setup: Oversold RSI 26, near Bollinger lower, volume surge. Score 6.6/10, moderate confidence.
Passes 7/9 gates (positive momentum, favorable risk/reward ratio, clean insider activity, news boost analyst 0.60, earnings proximity 105d clear, semi cycle peak clear, materials cycle peak clear). Suitability: speculative.
About Madrigal Pharmaceuticals, Inc.
About Madrigal Pharmaceuticals, Inc.
Rezdiffra (resmetirom), the first FDA-approved therapy for MASH, generated $958.4 million in net product revenue for Madrigal Pharmaceuticals in 2025, its first full calendar year of U.S. sales following the April 2024 commercial launch. Quarterly sales annualized at greater than $1.0 billion as of December 31, 2025. The European Commission granted a conditional marketing authorization in August 2025, and the company launched Rezdiffra in Germany in September 2025 — making it the first medication approved by both the FDA and EC for noncirrhotic MASH with moderate to advanced liver fibrosis (F2–F3).
Madrigal generates revenue entirely from prescriptions of Rezdiffra, a once-daily oral thyroid hormone receptor beta agonist. In the United States, the company sells through specialty pharmacy channels and has secured broad first-line formulary access across commercial payers. The company targets 315,000 identified U.S. MASH patients with F2–F3 fibrosis under specialist care as of 2023 market data, with the number of patients under specialist care estimated to have grown nearly 50% through 2025. Beyond Germany, country-by-country EU launches depend on completion of national reimbursement procedures. A U.S. patent listed in the FDA Orange Book covers Rezdiffra's commercial dosing regimen through February 2045, providing a long exclusivity runway. No competing MASH product is approved as of the filing date.
Show full overview
Rezdiffra's FDA approval is conditional under the Subpart H accelerated approval pathway, requiring confirmatory post-marketing studies. The MAESTRO-NASH trial (54-month outcomes, results expected 2028) must demonstrate hepatic clinical endpoint benefit to maintain the noncirrhotic MASH approval; the Phase 3 MAESTRO-NASH OUTCOMES trial (fully enrolled, results expected 2027) targets label expansion to compensated MASH cirrhosis (F4c). Failure to meet post-marketing commitments could trigger expedited withdrawal procedures under FDORA, and the EC's conditional marketing authorization must be renewed annually until converted to a standard authorization based on confirmatory data.
See also: Healthcare · Biotechnology
From Madrigal Pharmaceuticals, Inc.'s most recent 10-K filing, extracted June 11, 2026.
Recent developments
updated Nov 4, 2026Recent Developments — Madrigal Pharmaceuticals, Inc.
Latest news
- NEWS Madrigal Pharmaceuticals Faces Whistleblower Retaliation Complaint — fiscal.ai Nov 4, 2026 negative
- NEWS Madrigal Pharmaceuticals (MDGL) Stock May Be Below Fair Value Despite First Profit - Yahoo Finance — Yahoo Finance Nov 4, 2026 positive
- NEWS Madrigal Q3 Earnings: Why I'm Upgrading The Stock Again In 2026, This Time To Buy - Seeking Alpha — Seeking Alpha Nov 4, 2026 positive
- NEWS Madrigal Pharmaceuticals (MDGL) Stock Price Falls After Q3 Profit Turns Positive - Simply Wall St — Simply Wall St Nov 4, 2026 neutral
- NEWS Madrigal Pharmaceuticals (MDGL) Turns Profitable, Is The 42% Undervaluation Case Still Convincing? - Yahoo Finance — Yahoo Finance Nov 4, 2026 positive
Latest item Nov 4, 2026 · Generated 2026-11-05T11:29:01Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductRezdiffra10-K Item 1A: 'Our prospects are highly dependent on the success of our only approved product, Rezdiffra'
Material Events(8-K, last 90d)
- 2026-04-28Item 5.02LOWJulian C. Baker and Daniel J. Brennan reclassified from Class III and Class II to Class I directors on April 22, 2026, via simultaneous resignation and reappointment, solely to rebalance board class sizes before the 2026 Annual Meeting. No effective departure or new appointment.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker·1 ceiling hit
Volatile — 5.9% daily ATR makes tight stops impractical. Position-size conservatively.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $400.43: Risk below floor (2.1 < 2.5) triggers a hard block regardless of the otherwise-positive setup — overall score 6.6/10 and A.R:R 4.6:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 11%; Elevated put/call ratio: 6.40; Below-average business quality. Chart setup: Oversold RSI 26, near Bollinger lower, volume surge. Prior stop was $372.40. Score 6.6/10, moderate confidence.
Analyst target: $617.45 (+54.2% upside). Prior stop was $372.40. Stop-loss: $372.40.
Concentration risk — Product: Rezdiffra; Risk below floor (2.1 < 2.5); Value-trap signals (2/5): Margin compression (op margin 0.8%), Material insider selling (9 sells, 1.98% of cap).
Madrigal Pharmaceuticals, Inc. trades at a P/E of N/A (forward 41.6). TrendMatrix value score: 6.7/10. Verdict: Sell.
26 analysts rate MDGL, with a consensus score of 4.2/5. 18 analysts publish price targets averaging $686.
What does Madrigal Pharmaceuticals, Inc. do?Madrigal Pharmaceuticals is a biopharmaceutical company whose sole commercialized product, Rezdiffra (resmetirom),...
Madrigal Pharmaceuticals is a biopharmaceutical company whose sole commercialized product, Rezdiffra (resmetirom), received FDA accelerated approval in March 2024 as the first therapy for noncirrhotic MASH with moderate-to-advanced liver fibrosis. Rezdiffra generated $958.4 million in net product revenue in 2025; the European Commission granted conditional marketing authorization in August 2025 and Germany launched in September 2025.